Published : 2023-09-22

Efficacy of satralizumab therapy in the treatment of NMOSD

Małgorzata Krzyżanowska

Katarzyna Kozon

Jakub Olszewski

Andrzej Patyra

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with the presence of autoantibodies to anti–aquaporin-4 (AQP4-IgG). Interleukin-6 plays a key role in the pathogenesis of this disorder. Satralizumab, a humanized monoclonal antibody, targets the interleukin-6 receptor thus affecting the course of the disease. In Poland, satralizumab treatment has been offered free of charge by the public health service since November 2022. The results of SAkura studies demonstrate the long terms efficacy of satralizumab and provide evidence that satralizumab reduces the risk of relapse in patients with aquaporin-4-immunoglobulin G (IgG)–seropositive (AQP4-IgG+) NMOSD.

Keywords:

NMOSD, satralizumab, AQP4


Most read articles by the same author(s)


Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Krzyżanowska, M., Kozon, K., Olszewski, J., & Patyra, A. (2023). Efficacy of satralizumab therapy in the treatment of NMOSD. Prospects in Pharmaceutical Sciences, 21(3), 64–68. https://doi.org/10.56782/pps.166

Altmetric indicators


Cited by / Share


Licence


Editorial Team
Stefana Banacha 1
02-097 Warsaw, Poland
biuletynfarmacji@wum.edu.pl
Publisher:
Medical University of Warsaw
ul. Żwirki i Wigury 61
02-091 Warszawa

About:
Copyright 2021 by
OJS Support and Customization by LIBCOM
Platform & workfow by OJS/PKP